The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Optimizing transplantation outcomes in patients with AML
Eleni Gavriilaki, MD, PhD, G Papanicolaou Hospital, Thessaloniki, Greece, discusses recent advances in strategies to optimize the outcomes of patients with acute myeloid leukemia (AML) who receive an allogeneic transplant, including reduced-intensity conditioning (RIC) and more personalized treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
